Thrombosis syndromes (hypercoagulability): Pathology review

00:00 / 00:00



Thrombosis syndromes (hypercoagulability): Pathology review

Hematological system

Coagulation disorders


Vitamin K deficiency

Leukemoid reaction

Leukemoid reaction


Thrombosis syndromes (hypercoagulability): Pathology review

USMLE® Step 1 questions

0 / 6 complete


USMLE® Step 1 style questions USMLE

of complete

A 52-year-old woman, para 4 gravida 2 aborta 2, comes to the clinic for a follow-up appointment after a hospitalization. Two weeks ago, she had an incident of acute, severe abdominal pain and bloody stools. She was diagnosed with portal vein thrombosis. She denies similar episodes in the past. Medical history is notable for Legg-Calvé-Perthes disease as a child. She does not smoke, drink excessive alcohol, or use illicit drugs. She had 2 spontaneous abortions in the first trimester, following 2 successful pregnancies. Family history is remarkable for DVT in her maternal uncle and colon cancer in her father. The physician suspects an inherited condition. Which of the following will prompt further evaluation in this patient?  


At the emergency department, a 30 year old Caucasian female named Celia came in with pain and swelling in her right calf. She has a history of pregnancy loss and her mother has a history of recurrent episodes of venous thromboembolism. Her medical history is otherwise unremarkable. Coagulation studies show normal PTT. Next to Celia, there’s a 60 year old male called Nicholas who developed a painful lesion on his arm after starting anticoagulation therapy with warfarin. Now, there’s also a 26 year old African American female named Mary who has recurrent pregnancy losses. She was diagnosed with systemic lupus erythematosus about a year ago. She has no family history of thrombophilic disorder.

All of them suffer from thrombophilic disorders, or thrombosis syndromes, which are inherited or acquired diseases that predispose an individual to clot formation. Inherited disorders include factor V Leiden, prothrombin gene mutation, protein C and S deficiency, and antithrombin III deficiency, while the most important acquired disorder is antiphospholipid antibody syndrome. But before going into the individual thrombophilic disorders, let’s go through the normal coagulation system. The coagulation pathway is divided into an extrinsic and an intrinsic pathway, which join into a common pathway that ultimately result in the formation of fibrin clots. The extrinsic pathway starts when trauma damages a blood vessel, and exposes the cells under the endothelial layer, which have tissue factor in their membrane. Activated factor VII binds to tissue factor, forming a complex that then binds to and activates factor X. The intrinsic pathway starts when a circulating factor XII, activates factor XI, which then activates factor IX. Finally, factor IX forms a complex with factor VIII, and this complex binds to and activates factor X. In the common pathway. Activated factor X activates factor V, which converts prothrombin, or factor II, into thrombin. Thrombin then converts fibrinogen, or factor I, into fibrin, which cross-links to form a fibrin mesh that stabilizes the platelet plug. Now, prothrombin time, or PT assesses the extrinsic and common coagulation pathways, and partial thromboplastin time, or PTT assess the intrinsic and common coagulation pathways. Alright, but in order to prevent over-coagulation, the liver makes proteins C and S, which are vitamin K-dependent anticoagulant factors. In the presence of protein S as a cofactor, protein C acts by enzymatically inactivating factors V and VIII. Finally, a protein called antithrombin III inhibits factor X and factor II.


Thrombosis syndromes, also known as hypercoagulability, are a group of disorders characterized by an increased tendency to develop blood clots. These disorders can be inherited or acquired, and they can affect different parts of the body, including the veins and arteries. Thrombosis syndromes can be inherited, like factor V Leiden, prothrombin gene mutation, protein C and S deficiency, antithrombin III deficiency, or acquired like antiphospholipid syndrome.

Diagnosis can be made based on clinical presentation, coagulation studies, more specific lab tests like ELISA for antiphospholipid antibodies, as well as genetic testing to detect the specific mutations. Treatment involves a combination of anticoagulant therapy, lifestyle modifications, and management of the underlying conditions. Anticoagulant medications, such as warfarin and heparin, can help prevent blood clots from forming or growing.


  1. "Robbins Basic Pathology" Elsevier (2017)
  2. "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
  3. "Factor V Leiden thrombophilia" Genetics in Medicine (2010)
  4. "Diagnosis and management offactor V Leiden" Expert Review of Hematology (2016)
  5. "Technical standards and guidelines: Venous thromboembolism (Factor V Leiden and prothrombin 20210G>A testing): A disease-specific supplement to the standards and guidelines for clinical genetics laboratories" Genetics in Medicine (2005)
  6. "Laboratory Diagnostics in Thrombophilia" Hämostaseologie (2019)
  7. "Antiphospholipid Syndrome" Progress in Cardiovascular Diseases (2009)
  8. "Antiphospholipid syndrome: review. South Med J" Sammaritano LR (2005)

Copyright © 2023 Elsevier, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Cookies are used by this site.

USMLE® is a joint program of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). COMLEX-USA® is a registered trademark of The National Board of Osteopathic Medical Examiners, Inc. NCLEX-RN® is a registered trademark of the National Council of State Boards of Nursing, Inc. Test names and other trademarks are the property of the respective trademark holders. None of the trademark holders are endorsed by nor affiliated with Osmosis or this website.